[Skip to Navigation]
February 1995

Intralesional Bleomycin for Acquired Immunodeficiency Syndrome-Associated Cutaneous Kaposi's Sarcoma

Author Affiliations

Service ORL du Pr Soudant Hôpital Pitié Salpétrière 83 Bd de l'Hôpital 75013 Paris Cedex, France

Paris, France

Arch Dermatol. 1995;131(2):228. doi:10.1001/archderm.1995.01690140114026

The treatment of acquired immunodeficiency syndrome (AIDS)—associated Kaposi's sarcoma (KS) is controversial.1 Local treatments include the argon laser,2 cryotherapy,3 and intralesional vinblastine.3 We report our experience with intralesional bleomycin used in the treatment of cutaneous KS.

Methods.  Since September 1987, two observers used intralesional bleomycin to treat 15 men with biopsyproven AIDS-associated KS. The median age was 35 years (range, 29 through 63 years). The known risk factor was homosexuality in nine cases and not known in six cases. At inclusion, the median CD4 cell count in 13 patients was 199×109/L (range, 1 to 634×109/L)Cutaneous lesions (not previously treated) were located on both the face and the body. The size of the lesions ranged from 2 to 15 mm. Both macular and nodular lesions were observed.The median number of lesions treated per patient was eight (range, one through 19). Two

Add or change institution